PCSK9-targeted Therapies Market Expected to Witness Significant Growth by 2036, Driven by Innovative Lipid-Lowering Therapies and Expanding High-Risk Patient Population | DelveInsight

The PCSK9-targeted Therapies market is anticipated to witness substantial growth across the seven major markets (7MM) during the forecast period (2022-2036), driven by the increasing prevalence of dyslipidemia, hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD), along with expanding adoption of innovative lipid-lowering therapies. Continued advancements in monoclonal antibodies, small interfering RNA (siRNA)-based therapies, recombinant fusion proteins, oral small molecules, and gene-editing technologies are expected to transform the treatment landscape and improve long-term cardiovascular outcomes for high-risk patients.

DelveInsight's "PCSK9-targeted Therapies Market Insight, Epidemiology, and Market Forecast-2036" provides a comprehensive assessment of the evolving market by analyzing epidemiological trends, current treatment practices, marketed products, emerging pipeline therapies, competitive landscape, reimbursement environment, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted market dynamics, therapy uptake, pricing trends, patient populations, and unmet medical needs to help stakeholders identify future commercial opportunities.
The report also provides detailed insights into disease burden, treatment algorithms, patient journey, competitive intelligence, market access, and reimbursement scenarios while assessing the impact of next-generation PCSK9-targeted therapies expected to enter the market during the forecast period.

To know in detail about the PCSK9-targeted Therapies market outlook, treatment landscape, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/pcsk9-inhibitors-psck9i-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the PCSK9-targeted Therapies Market Report

• The PCSK9-targeted Therapies market across the 7MM is projected to experience robust growth through 2036, supported by increasing treatment adoption, expanding eligible patient populations, and the anticipated launch of innovative oral and next-generation lipid-lowering therapies.
• According to DelveInsight estimates, the total PCSK9-targeted Therapies market in the 7MM was valued at nearly USD 3,000 million in 2025 and is expected to expand significantly during the forecast period.
• The United States accounted for the largest share of the market, generating nearly USD 2,500 million in 2025, while Germany represented the largest market among the EU4 and the UK.
• There are currently four marketed PCSK9-targeted therapies available across major markets: REPATHA (evolocumab), PRALUENT (alirocumab), LEQVIO (inclisiran), and LEROCHOL (lerodalcibep), representing monoclonal antibodies, siRNA therapy, and recombinant fusion protein technologies.
• The late-stage development pipeline includes promising candidates such as Enlicitide Decanoate (MK-0616) from Merck Sharp & Dohme, Laroprovstat (AZD0780) from AstraZeneca, and VERVE-102 from Verve Therapeutics, which aim to improve treatment convenience and patient adherence.
• Among emerging products, LEQVIO is expected to remain a major growth driver because of its twice-yearly dosing schedule, while upcoming oral therapies may further expand treatment adoption among patients requiring long-term LDL cholesterol reduction.
• PCSK9-targeted therapies continue to receive strong support from international treatment guidelines owing to their ability to achieve substantial reductions in LDL cholesterol and improve cardiovascular outcomes in patients with familial hypercholesterolemia, statin intolerance, and established ASCVD.

Key Factors Driving the PCSK9-targeted Therapies Market
Rising Burden of Hypercholesterolemia and Cardiovascular Disease

The growing prevalence of dyslipidemia, familial hypercholesterolemia, ASCVD, peripheral artery disease, acute coronary syndrome, and other cardiovascular disorders continues to increase demand for advanced lipid-lowering therapies. As cardiovascular disease remains one of the leading causes of mortality worldwide, effective LDL cholesterol reduction has become a major therapeutic priority.

Innovation Across Multiple Therapeutic Platforms
The PCSK9 therapeutic landscape has rapidly evolved beyond monoclonal antibodies to include siRNA therapies, recombinant fusion proteins, oral small molecules, synthetic cyclic peptides, and gene therapy. This diversified innovation pipeline is expected to improve patient convenience while expanding treatment options for both familial and non-familial hypercholesterolemia.

Strong Clinical Evidence and Guideline Support
Large cardiovascular outcome trials have demonstrated that PCSK9-targeted therapies produce profound reductions in LDL cholesterol while significantly lowering the risk of major adverse cardiovascular events. These findings have resulted in widespread inclusion of PCSK9 inhibitors within major international clinical practice guidelines for high-risk cardiovascular patients requiring additional lipid lowering beyond maximally tolerated statin therapy.
Growing Pipeline of Oral PCSK9 Therapies
Emerging oral PCSK9 inhibitors, including Enlicitide Decanoate and Laroprovstat, are expected to address one of the major barriers associated with injectable therapies by offering improved treatment convenience and potentially enhancing long-term patient adherence. Their anticipated commercialization may substantially broaden the eligible treatment population across the seven major markets.

PCSK9-targeted Therapies Market Analysis

PCSK9-targeted therapies have become an important component of lipid-lowering treatment for patients who remain unable to achieve recommended LDL cholesterol targets despite maximally tolerated statin therapy or who suffer from familial hypercholesterolemia and established atherosclerotic cardiovascular disease. Since the first approvals in 2015, these therapies have consistently demonstrated the ability to reduce LDL cholesterol levels by approximately 60% while significantly lowering the risk of cardiovascular events in high-risk populations.

The current competitive landscape is led by REPATHA, PRALUENT, LEQVIO, and the recently approved LEROCHOL, while several late-stage pipeline candidates are expected to introduce greater treatment flexibility through oral administration, extended dosing intervals, and novel mechanisms of action. The continued expansion of eligible patient populations, combined with improving physician awareness and evolving treatment guidelines, is expected to sustain long-term market growth.

Despite their proven efficacy, PCSK9-targeted therapies continue to face challenges related to reimbursement restrictions, treatment costs, administrative hurdles, and underdiagnosis of familial hypercholesterolemia.

Nevertheless, increasing adoption of innovative therapies, expanding reimbursement frameworks, and the arrival of more convenient oral and gene-based treatment approaches are anticipated to accelerate market penetration throughout the forecast period.

Get a Free sample for the PCSK9-targeted Therapies Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/pcsk9-inhibitors-psck9i-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

PCSK9-targeted Therapies Competitive Landscape

The PCSK9-targeted therapies market has evolved into one of the most dynamic segments within cardiovascular medicine, driven by continuous innovation in lipid-lowering technologies and increasing demand for therapies capable of achieving profound reductions in low-density lipoprotein cholesterol (LDL-C). The competitive landscape currently includes monoclonal antibodies, small interfering RNA (siRNA)-based therapies, recombinant fusion proteins, and a growing pipeline of oral small-molecule and gene-editing therapies designed to improve patient convenience and long-term treatment adherence.

Currently marketed therapies include REPATHA (evolocumab) from Amgen, PRALUENT (alirocumab) from Sanofi/Regeneron Pharmaceuticals, LEQVIO (inclisiran) from Novartis/Alnylam Pharmaceuticals, and LEROCHOL (lerodalcibep) from LIB Therapeutics. These therapies have established strong clinical efficacy in reducing LDL-C levels and lowering cardiovascular risk among patients with familial hypercholesterolemia, clinical ASCVD, and statin intolerance.

Looking ahead, the next phase of market competition is expected to be driven by late-stage pipeline candidates such as Enlicitide Decanoate (MK-0616), Laroprovstat (AZD0780), and VERVE-102, which aim to expand treatment options through oral administration, innovative delivery platforms, and gene-editing approaches.

Emerging Therapies Driving the PCSK9-targeted Therapies Market

Enlicitide Decanoate (MK-0616): Merck Sharp & Dohme
Enlicitide Decanoate (MK-0616) is an investigational oral macrocyclic peptide designed to inhibit PCSK9 using the same biological pathway as injectable monoclonal antibodies while offering the convenience of once-daily oral administration. The therapy is currently being evaluated in multiple Phase III clinical trials for patients requiring additional LDL-C reduction despite standard lipid-lowering therapy.
The program achieved an important milestone in September 2025, when Merck announced positive topline results from the Phase III CORALreef Lipids trial, demonstrating that the study met its primary and key secondary endpoints for efficacy and safety. In December 2025, the US FDA selected Enlicitide Decanoate for the CNPV pilot program, and the company announced plans to submit a New Drug Application (NDA) in early 2026.

Laroprovstat (AZD0780): AstraZeneca
Laroprovstat (AZD0780) is AstraZeneca's investigational oral small-molecule PCSK9 inhibitor being developed for patients with elevated LDL cholesterol levels that remain inadequately controlled with statin therapy. The therapy is intended to provide a convenient oral alternative while maintaining effective LDL-C reduction.
The drug is currently in Phase III clinical development. In March 2025, AstraZeneca presented positive results from the Phase IIb PURSUIT trial at the American College of Cardiology (ACC) Annual Scientific Session. Subsequently, in September 2025, the company registered its Phase III clinical trial in China for adults with confirmed cardiovascular disease or individuals at high cardiovascular risk.

VERVE-102: Verve Therapeutics
VERVE-102 is an investigational gene-editing therapy designed to provide durable LDL-C reduction by targeting the PCSK9 gene. The therapy represents one of the most innovative approaches currently under development and has the potential to significantly reduce long-term treatment burden through a one-time therapeutic intervention. According to the report, VERVE-102 is currently in Phase I clinical development.

Recaticimab: Hengrui Medicine
Recaticimab is a fully human monoclonal IgG1 antibody targeting PCSK9 that prevents degradation of LDL receptors, thereby enhancing LDL cholesterol clearance. In January 2025, the National Medical Products Administration (NMPA) approved Recaticimab for adults with primary hypercholesterolemia (including heterozygous familial and non-familial disease) and mixed dyslipidemia to be used alongside diet and statin therapy or as monotherapy when appropriate.

Recent Developments in the PCSK9-targeted Therapies Market

• In December 2025, the US FDA approved LEROCHOL (lerodalcibep-liga) from LIB Therapeutics for adults with elevated LDL cholesterol, expanding treatment options within the PCSK9 therapeutic class.
• In September 2025, Merck reported positive topline results from the Phase III CORALreef Lipids trial evaluating Enlicitide Decanoate (MK-0616) in adults with hypercholesterolemia receiving moderate- or high-intensity statin therapy.
• In December 2025, the US FDA selected Enlicitide Decanoate for the CNPV pilot program, with an NDA submission planned for early 2026.
• In March 2025, AstraZeneca presented positive Phase IIb PURSUIT clinical data for Laroprovstat (AZD0780) during the American College of Cardiology Annual Scientific Session.
• In January 2025, Recaticimab received regulatory approval in China for adults with primary hypercholesterolemia and mixed dyslipidemia, providing an additional therapeutic option within the global PCSK9 treatment landscape.

What are PCSK9-targeted Therapies?
PCSK9-targeted therapies are advanced lipid-lowering treatments that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a protein responsible for promoting degradation of low-density lipoprotein receptors (LDLR) in the liver. By preventing PCSK9 activity, these therapies increase the number of LDL receptors available to remove LDL cholesterol from circulation, resulting in substantial reductions in LDL-C levels and lower cardiovascular risk.
These therapies are primarily indicated for patients with familial hypercholesterolemia (heterozygous and homozygous forms), clinical atherosclerotic cardiovascular disease (ASCVD), mixed dyslipidemia, and individuals who remain unable to achieve LDL-C targets despite maximally tolerated statin therapy or who are intolerant to statins. Current treatment options include monoclonal antibodies, siRNA therapies, recombinant fusion proteins, while oral small-molecule inhibitors and gene-editing therapies are expected to further expand future treatment options.
PCSK9-targeted Therapies Epidemiology Segmentation
The DelveInsight report provides detailed epidemiological and target patient pool analysis across the seven major markets for the period 2022-2036, segmented into:

• Total Cases of Dyslipidemia
• Total Cases of Hypercholesterolemia (Familial and Non-Familial)
• Heterozygous Familial Hypercholesterolemia (HeFH)
• Homozygous Familial Hypercholesterolemia (HoFH)
• Atherosclerotic Cardiovascular Disease (ASCVD)
• Peripheral Artery Disease (PAD)
• Acute Coronary Syndrome (Acute Myocardial Infarction and Unstable Angina)
• Stroke
• Coronary Revascularization (CABG and PCI)
• Total Treatment-Eligible Cases
• Total Statin-intolerant/Uncontrolled LDL-C Patient Population
• Country-specific Epidemiology Across the United States, EU4 and the United Kingdom, and Japan

Download the report to understand key epidemiology trends and future commercial opportunities in the PCSK9-targeted Therapies market:
https://www.delveinsight.com/sample-request/pcsk9-inhibitors-psck9i-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the PCSK9-targeted Therapies Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Companies: Amgen, Sanofi, Regeneron Pharmaceuticals, Novartis, Alnylam Pharmaceuticals, LIB Therapeutics, Merck Sharp & Dohme, AstraZeneca, Verve Therapeutics, Hengrui Medicine, Aqur Biosciences, and others
• Marketed Therapies: REPATHA (evolocumab), PRALUENT (alirocumab), LEQVIO (inclisiran), LEROCHOL (lerodalcibep), and others
• Emerging Therapies: Enlicitide Decanoate (MK-0616), Laroprovstat (AZD0780), VERVE-102, Recaticimab, AQR-008, and others
• Target Indications Covered: Dyslipidemia, Hypercholesterolemia (Familial and Non-Familial), Atherosclerotic Cardiovascular Disease (ASCVD), Peripheral Artery Disease (PAD), Acute Coronary Syndrome (ACS), Stroke, Coronary Revascularization (CABG and PCI), and Familial Hypercholesterolemia (HeFH and HoFH)
• Market Dynamics: Market Drivers, Barriers, Opportunities, Challenges, and Future Growth Trends
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, Pricing Trends, Therapy Uptake Analysis, Competitive Benchmarking, and Market Share Assessment
• Market Access & Reimbursement: Country-specific pricing and reimbursement landscape across the United States, EU4, the United Kingdom, and Japan
• Patient Journey, KOL Insights, Analyst Perspectives, Unmet Needs, and Future Commercial Opportunities

To know more about companies developing innovative PCSK9-targeted therapies, visit:
https://www.delveinsight.com/sample-request/pcsk9-inhibitors-psck9i-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
• PCSK9-targeted Therapies Market Report Introduction
• Executive Summary
• Key Insights
• Key Events and Recent Developments
• Epidemiology and Market Forecast Methodology
• PCSK9-targeted Therapies Market Overview at a Glance
• Clinical Landscape by Molecule Type and Route of Administration
• Disease Background and Overview
• Mechanism of Action of PCSK9-targeted Therapies
• Types of PCSK9-targeted Therapies
• Treatment Guidelines and Clinical Practice
• Epidemiology and Target Patient Population
• Treatment-Eligible Patient Pool Analysis
• Statin-intolerant/Uncontrolled LDL-C Population Assessment
• Marketed Therapies
• Emerging Therapies
• Drug Profiles and Clinical Development
• Market Size and Forecast (2022-2036)
• Therapy Uptake Analysis
• Pricing Trends and Analogue Analysis
• Conjoint Analysis
• Key Opinion Leader (KOL) Perspectives
• SWOT Analysis
• Market Access and Reimbursement
• Country-specific Reimbursement Landscape
• Unmet Needs
• Future Market Opportunities
• Appendix
• Report Methodology
• DelveInsight Capabilities
• Disclaimer

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.